Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding.
Department of Radiology, Kings College Hospital, London, United Kingdom (D.J.Q.); Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, Ontario, Canada; and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.W.E., J.I.W.).
Daniel J
DJ
Quinlan
John W
JW
Eikelboom
Jeffrey I
JI
Weitz
D000925:Anticoagulants / Q000009:adverse effects*; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D004338:Drug Combinations; D005164:Factor IX / Q000627:therapeutic use*; D005167:Factor VII / Q000627:therapeutic use*; D005170:Factor X / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011516:Prothrombin / Q000627:therapeutic use*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D004338:Drug Combinations; D006490:Hemostatics; C525441:factor IX, factor VII, factor X, prothrombin drug combination; D014812:Vitamin K; C025667:prothrombin complex concentrates; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X
Editorials; hemorrhage; prothrombin complex concentrates; randomized controlled trial; warfarin